Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: Comparison with dexamethasone and hydrocortisone

Japanese Journal of Ophthalmology

Volumn 48, Issue 3, 2004, Pages 236-242

  Yeung, Chi Kong ^a   Chan, Kwok Ping ^a   Chan, Carmen K M ^a   Pang, Chi Pui ^a   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Corticosteroids; Cytotoxicity; Pigmented RPE cells; Triamcinolone

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DEXAMETHASONE; GLUTAMINE; HYDROCORTISONE SODIUM SUCCINATE; PENICILLIN G; STREPTOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE;

ANALYSIS OF VARIANCE; ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; SERUM;

CELL DIVISION; CELL LINE; CELL SURVIVAL; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MICROSCOPY, PHASE-CONTRAST; OSMOLAR CONCENTRATION; PIGMENT EPITHELIUM OF EYE; TIME FACTORS; TRIAMCINOLONE;

EID: 2542467968     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-003-0053-8     Document Type: Article

References (34)

1. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
2. Martidis A, Duker JS, Greenberg P, et al. Intravitreal triamcinolone for refractory diabetic macular degeneration. Ophthalmology 2002;109:920-927.
3. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87:24-27.
4. Jonas JB, Kressig I, Söfker A, Degenring RE Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
5. Danis RP, Ciulla TA, Pratt LM, Aniker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
6. Penfold PL, Wen L, Madigan MC, King NJC, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002;43: 3125-3130.
7. Zamir E, Read RW, Smith RE, Wang RC, Rao NA. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. Ophthalmology 2002;109:798-805.
8. Yoshikawa K, Kotake S, Ichiishi A, Sasamoto Y, Kosaka S, Matsuda H. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 1995;39:71-76.
9. Ciulla TA, Criswell MH, Danis RP, Hill PE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2000;119:399-404.
10. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neo-vascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma 2001;10:284-287.
11. Tano Y, Chanfler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
12. Sakamoto T, Miyazaka M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
13. Chandler DB, Hida T, Sheta S, Proia AD, Machemer R. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol 1987;225:259-265.
14. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-432.
15. Modarres M, Parvaresh MM, Peymen GA. Accidental subretinal injection of triamcinolone acetonide. Ophthalmol Surg Lasers 1998;29:935-938.
16. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55.
17. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996;62:155-169.
18. Alizadeh M, Gelfman CM, Bench SR, Hjelmeland LM. Expression and splicing of FGF receptor mRNAs during APRE-19 cell differentiation in vitro. Invest Ophthalmol Vis Sci 2000;41:2357-2362.
19. Macky TA, Oelkers C, Rix U, et al. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem 2002;45: 1122-1127.
20. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
21. Kivilcim M, Peymen GA, El-Dessouky ES, Kazi AA, Cheema R. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmol Surg Lasers 2000;31:474-478.
22. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlu-sion. Graefes Arch Clin Exp Ophthalmol 2002;240:782-783.
23. Jonas JB, Degenring RE Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular edema. Klin Monatsbl Augenheilkd 2002;219:429-432.
24. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27.
25. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-432.
26. Modarres M, Parvaresh MM, Peymen GA. Accidental subretinal injection of triamcinolone acetonide. Ophthalmol Surg Lasers 1998;29:935-938.
27. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55.
28. Kong AN, Yu R, Lei W, Mandlekar S, Tan TH, Ucker DS. Differential activation of MAPK and ICE/ced-3 protease in chemical-induced apoptosis: the role of oxidative stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene expression and survival or activation of caspases leading to apoptosis. Restor Neurol Neuosci 1998;12:63-70.
29. He L, Poblenz AT, Medrano CJ, Fox DA. Lead and calcium produce rod photoreceptor cell apoptosis by opening the mitochondrial permeability transition pore. J Biol Chem 2000;275:12175-12184.
30. He L, Perkins GA, Poblenz AT, Harris JB, Hung M, Ellisman MH, et al. Bcl-xL overexpression blocks bax-mediated mitochondrial contact site formation and apoptosis in rod photoreceptors of lead-exposed mice. Proc Natl Acad Sci U S A 2003;100:1022-1027.
31. Cellerino A, Bahr M, Isenmann S. Apoptosis in the developing visual system. Cell Tissue Res 2000;301:53-69.
32. Blumenkranz MS, Claflin A, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. Arch Ophthalmol 1984;102:598-604.
33. Jaffe GF, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-3575.
34. Hainsworth DP, Pearson PA, Conklin JD, Ashton P. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther 1996:12:57-63.